Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
View ORCID ProfileManaf AlQahtani, View ORCID ProfileAbdulkarim Abdulrahman, Abdulrahman Almadani, Salman Yousif Alali, Alaa Mahmood Al Zamrooni, Amal Hamza Hejab, Ronán M Conroy, Pearl Wasif, Stephen L Atkin, Sameer Otoom, Manal Abduljalil
doi: https://doi.org/10.1101/2020.11.02.20224303
Manaf AlQahtani
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
2Bahrain Defence Force Hospital, Bahrain
MDAbdulkarim Abdulrahman
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
3Sheikh Mohammed bin Khalifa Cardiac Centre, Bahrain
MDAbdulrahman Almadani
2Bahrain Defence Force Hospital, Bahrain
MDSalman Yousif Alali
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
2Bahrain Defence Force Hospital, Bahrain
MDAlaa Mahmood Al Zamrooni
4Salmaniya Medical Complex, Manama, Bahrain
MDAmal Hamza Hejab
1National Task Force for Combating the Corona Virus (COVID-19), Bahrain
MDRonán M Conroy
5Royal College of Surgeons in Ireland, Dublin, Ireland
PhDPearl Wasif
6Royal College of Surgeons in Ireland-Bahrain
BScStephen L Atkin
6Royal College of Surgeons in Ireland-Bahrain
PhDSameer Otoom
6Royal College of Surgeons in Ireland-Bahrain
PhDManal Abduljalil
2Bahrain Defence Force Hospital, Bahrain
MD
Data Availability
Data will be made available upon reasonable request
Posted November 04, 2020.
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
Manaf AlQahtani, Abdulkarim Abdulrahman, Abdulrahman Almadani, Salman Yousif Alali, Alaa Mahmood Al Zamrooni, Amal Hamza Hejab, Ronán M Conroy, Pearl Wasif, Stephen L Atkin, Sameer Otoom, Manal Abduljalil
medRxiv 2020.11.02.20224303; doi: https://doi.org/10.1101/2020.11.02.20224303
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
Manaf AlQahtani, Abdulkarim Abdulrahman, Abdulrahman Almadani, Salman Yousif Alali, Alaa Mahmood Al Zamrooni, Amal Hamza Hejab, Ronán M Conroy, Pearl Wasif, Stephen L Atkin, Sameer Otoom, Manal Abduljalil
medRxiv 2020.11.02.20224303; doi: https://doi.org/10.1101/2020.11.02.20224303
Subject Area
Subject Areas
- Addiction Medicine (410)
- Allergy and Immunology (725)
- Anesthesia (214)
- Cardiovascular Medicine (3086)
- Dermatology (260)
- Emergency Medicine (462)
- Epidemiology (13014)
- Forensic Medicine (13)
- Gastroenterology (860)
- Genetic and Genomic Medicine (4834)
- Geriatric Medicine (445)
- Health Economics (750)
- Health Informatics (3057)
- Health Policy (1101)
- Hematology (410)
- HIV/AIDS (956)
- Medical Education (453)
- Medical Ethics (119)
- Nephrology (499)
- Neurology (4606)
- Nursing (244)
- Nutrition (684)
- Oncology (2385)
- Ophthalmology (673)
- Orthopedics (268)
- Otolaryngology (333)
- Pain Medicine (300)
- Palliative Medicine (87)
- Pathology (514)
- Pediatrics (1239)
- Primary Care Research (520)
- Public and Global Health (7189)
- Radiology and Imaging (1601)
- Respiratory Medicine (943)
- Rheumatology (459)
- Sports Medicine (403)
- Surgery (509)
- Toxicology (65)
- Transplantation (221)
- Urology (189)